Teijin Limited announced that it has resolved at its Board of Directors meeting held on May 31,2023 to transfer the rights and obligations arising from its contract development and manufacturing organization (CDMO) business for regenerative medicines, including cell and gene therapies, to TEIJIN REGENET CO.,LTD., a new company to be established (hereinafter, the "successor company"), through an incorporation-type company split (hereinafter, the "Company Split"), with August 1, 2023 as effective date (planned). The Company Split will be implemented to promote agile and flexible business strategy for the purpose of developing and expanding the CDMO business for regenerative medicines, including cell and gene therapies (hereinafter, the "Business"). Board of Directors resolution on the Company Split plan: May 31, 2023.

Planned date of the Company Split (effective date): August 1, 2023 (planned).